Alnylam’s Patisiran ATTR-CM Opportunity Boosted By New APOLLO-B Data

 
• By Mandy Jackson

Phase III results for Onpattro (patisiran) in ATTR cardiomyopathy pave a path to approval – though the competitive profile is in question – and foreshadow potential success for follow-on drug vutrisiran.

stethoscope and red heart on blue background
ATTR cardiomyopathy significantly increases the market size for Onpattro • Source: Shutterstock

More from Clinical Trials

More from R&D